Supplementary figure 1. Flow chart of studies selection process for polymorphisms in *XRCC1* genes.



Supplementary figure 2. Flow chart of studies selection process for polymorphisms in *XRCC2* genes.



Supplementary figure 3. Flow chart of studies selection process for polymorphisms in *XRCC3* genes.



Supplementary figure 4. Flow chart of studies selection process for polymorphisms in *XRCC4* genes.



Supplementary figure 5. Flow chart of studies selection process for polymorphisms in *XRCC7* genes.



Supplementary figure 6. Sensitivity analysis for *XRCC1*-rs25487 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 7. Sensitivity analysis for *XRCC1*-rs25489 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 8. Sensitivity analysis for *XRCC1*-rs915927 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 9. Sensitivity analysis for *XRCC1*-rs1799782 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 10. Sensitivity analysis for *XRCC1*-rs3213245 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 11. Sensitivity analysis for *XRCC2*-rs3218536 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 12. Sensitivity analysis for *XRCC3*-rs861539 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 13. Sensitivity analysis for *XRCC3*-rs1799796 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 14. Sensitivity analysis for *XRCC4*-rs1805377 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 15. Sensitivity analysis for *XRCC4*-rs6869366 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 16. Sensitivity analysis for *XRCC4*-rs28360071 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 17. Sensitivity analysis for *XRCC7*-rs7003908 polymorphism and the risk of urological neoplasms (allelic comparison B vs. A).



Supplementary figure 18. Begg's funnel plot for publication bias under *XRCC1*-rs25487 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 19. Begg's funnel plot for publication bias under *XRCC1*-rs25489 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 20. Begg's funnel plot for publication bias under *XRCC1*-rs915927 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 21. Begg's funnel plot for publication bias under *XRCC1*-rs1799782 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 22. Begg's funnel plot for publication bias under *XRCC1*-rs3213245 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 23. Begg's funnel plot for publication bias under *XRCC2*-rs3218536 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 24. Begg's funnel plot for publication bias under *XRCC3*-rs861539 (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 25. Begg's funnel plot for publication bias under *XRCC3*-rs1799796 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 26. Begg's funnel plot for publication bias under *XRCC4*-rs1805377 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 27. Begg's funnel plot for publication bias under *XRCC4*-rs6869366 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 28. Begg's funnel plot for publication bias under *XRCC4*-rs28360071 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 29. Begg's funnel plot for publication bias under *XRCC7*-rs7003908 polymorphism (allelic comparison B vs. A). The x-axis log (OR) and the y-axis is natural logarithm of OR. The horizontal line in the figure represents the overall estimated log (OR). The two diagonal lines indicate the pseudo 95% confidence limits of the effect estimate. Log (OR) = log-transformed OR, OR = odds ratio.



Supplementary figure 30. Linkage disequilibrium analyses for *XRCC1* polymorphisms in populations from 1000 genomes. The number of each cell represents r^2 and white color cells shows no LD between polymorphisms. Population descriptors: CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; JPT: Japanese in Tokyo, Japan; YRI: Yoruba in Ibadan, Nigeria. The rs numbers are SNP IDs taken from National Center for Biotechnology Information (NCBI).



Supplementary figure 31. Linkage disequilibrium analyses for *XRCC3 and XRCC4* polymorphisms in populations from 1000 genomes. The number of each cell represents r^2 and white color cells shows no LD between polymorphisms. Population descriptors: CEU: Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han Chinese in Beijing, China; JPT: Japanese in Tokyo, Japan; YRI: Yoruba in Ibadan, Nigeria. The rs numbers are SNP IDs taken from National Center for Biotechnology Information (NCBI).



Supplementary table 1. Search strategies for each gene and the finally eligible articles included.

Gene	Search Strategy	Eligible Publications	Eligible Studies
XRCC1	(X-Ray Repair Cross Complementing 1 OR *XRCC1*) AND (polymorphism OR variation) AND (carcinoma OR cancer OR neoplasm OR adenocarcinoma OR tumor OR tumour)	35	80
XRCC2	(X-Ray Repair Cross Complementing 2 OR *XRCC2*) AND (polymorphism OR variation) AND (carcinoma OR cancer OR neoplasm OR adenocarcinoma OR tumor OR tumour)	3	3
XRCC3	(X-Ray Repair Cross Complementing 3 OR *XRCC3*) AND (polymorphism OR variation) AND (carcinoma OR cancer OR neoplasm OR adenocarcinoma OR tumor OR tumour)	22	29
XRCC4	(X-Ray Repair Cross Complementing 4 OR *XRCC4*) AND (polymorphism OR variation) AND (carcinoma OR cancer OR neoplasm OR adenocarcinoma OR tumor OR tumour)	6	12
XRCC7	(X-Ray Repair Cross Complementing 7 OR *XRCC7*) AND (polymorphism OR variation) AND (carcinoma OR cancer OR neoplasm OR adenocarcinoma OR tumor OR tumour)	5	6

Supplementary table 2. Details of the sensitivity analyses for the polymorphisms in *XRCC* genes and the risk of urological neoplasms.

Polymorphism	Comparison	Study Omitted	Estimate	[95% Confident Interval]	Effect Model
XRCC1-rs915927	B vs. A	Sak *et al.*	1.015	0.926-1.113	Fixed
		Matullo *et al.*	1.001	0.919-1.090	
		Matullo *et al.*	0.968	0.888-1.055	
		Agalliu *et al.*	1.064	0.947-1.197	
		Agalliu *et al.*	1.006	0.927-1.093	
	BA vs. AA	Sak *et al.*	1.009	0.852-1.194	Fixed
		Matullo *et al.*	1.011	0.870-1.175	
		Matullo *et al.*	0.941	0.805-1.100	
		Agalliu *et al.*	1.078	0.888-1.309	
		Agalliu *et al.*	1.031	0.891-1.194	
	BA+BB vs. AA	Sak *et al.*	1.022	0.872-1.197	Fixed
		Matullo *et al.*	1.011	0.877-1.165	
		Matullo *et al.*	0.939	0.810-1.088	
		Agalliu *et al.*	1.094	0.912-1.312	
		Agalliu *et al.*	1.028	0.896-1.180	
	BB vs. AA	Sak *et al.*	1.008	0.837-1.214	Fixed
		Matullo *et al.*	0.981	0.825-1.166	
		Matullo *et al.*	0.923	0.774-1.100	
		Agalliu *et al.*	1.091	0.862-1.380	
		Agalliu *et al.*	1.000	0.846-1.183	
	BB vs. AA+AB	Sak *et al.*	1.019	0.885-1.172	Fixed
		Matullo *et al.*	0.993	0.867-1.136	
		Matullo *et al.*	0.975	0.852-1.115	
		Agalliu *et al.*	1.074	0.882-1.308	
		Agalliu *et al.*	0.991	0.869-1.130	
XRCC1-rs25489	B vs. A	Sak *et al.*	1.152	0.992-1.337	Random
		Stern *et al.*	1.173	1.012-1.360	
		Stern *et al.*	1.168	1.012-1.347	
		Figueroa *et al.*	1.178	1.004-1.383	

	Mittal *et al.*	1.194	1.023-1.394	
	Mittal *et al.*	1.204	1.041-1.393	
	Wang *et al.*	1.095	0.995-1.206	
	Xu *et al.*	1.175	1.009-1.368	
	vanGils *et al.*	1.166	1.007-1.350	
	Agalliu *et al.*	1.172	0.999-1.376	
	Agalliu *et al.*	1.181	1.023-1.363	
	Mittal *et al.*	1.193	1.022-1.394	
	Zhu *et al.*	1.178	0.998-1.392	
BA vs. AA	Sak *et al.*	1.459	1.176-1.812	Random
	Stern *et al.*	1.481	1.205-1.821	
	Stern *et al.*	1.455	1.192-1.776	
	Figueroa *et al.*	1.510	1.214-1.879	
	Mittal *et al.*	1.430	1.161-1.761	
	Mittal *et al.*	1.425	1.162-1.747	
	Wang *et al.*	1.372	1.146-1.641	
	Xu *et al.*	1.488	1.203-1.840	
	vanGils *et al.*	1.465	1.192-1.802	
	Agalliu *et al.*	1.508	1.211-1.879	
	Agalliu *et al.*	1.492	1.224-1.819	
	Mittal *et al.*	1.375	1.149-1.645	
	Zhu *et al.*	1.523	1.234-1.879	
BA+BB vs. AA	Sak *et al.*	1.269	1.134-1.421	Fixed
	Stern *et al.*	1.286	1.152-1.436	
	Stern *et al.*	1.280	1.147-1.427	
	Figueroa *et al.*	1.310	1.163-1.475	
	Mittal *et al.*	1.285	1.146-1.440	
	Mittal *et al.*	1.290	1.153-1.444	

	Wang *et al.*	1.210	1.080-1.355	
	Xu *et al.*	1.289	1.152-1.442	
	vanGils *et al.*	1.281	1.147-1.429	
	Agalliu *et al.*	1.304	1.158-1.469	
	Agalliu *et al.*	1.291	1.157-1.440	
	Mittal *et al.*	1.263	1.127-1.415	
	Zhu *et al.*	1.323	1.172-1.494	
BB vs. AA	Sak *et al.*	0.994	0.802-1.232	Fixed
	Stern *et al.*	0.996	0.806-1.232	
	Stern *et al.*	0.996	0.806-1.232	
	Figueroa *et al.*	0.997	0.804-1.237	
	Mittal *et al.*	1.034	0.814-1.314	
	Mittal *et al.*	1.053	0.836-1.328	
	Wang *et al.*	0.955	0.770-1.184	
	Xu *et al.*	1.000	0.807-1.239	
	vanGils *et al.*	0.996	0.806-1.232	
	Agalliu *et al.*	0.990	0.799-1.226	
	Agalliu *et al.*	0.996	0.806-1.232	
	Mittal *et al.*	1.045	0.824-1.324	
	Zhu *et al.*	0.899	0.692-1.168	
BB vs. AA+AB	Sak *et al.*	0.841	0.685-1.033	Fixed
	Stern *et al.*	0.844	0.689-1.035	
	Stern *et al.*	0.844	0.689-1.035	
	Figueroa *et al.*	0.842	0.686-1.035	
	Mittal *et al.*	0.878	0.697-1.104	
	Mittal *et al.*	0.899	0.720-1.124	
	Wang *et al.*	0.813	0.662-0.999	

		Xu *et al.*	0.846	0.689-1.038	
		vanGils *et al.*	0.844	0.689-1.035	
		Agalliu *et al.*	0.838	0.682-1.029	
		Agalliu *et al.*	0.844	0.689-1.035	
		Mittal *et al.*	0.934	0.743-1.176	
		Zhu *et al.*	0.714	0.557-0.916	
XRCC1-rs3213245	B vs. A	Wang *et al.*	0.966	0.831-1.124	Fixed
		Sak *et al.*	0.899	0.706-1.144	
		Zhi *et al.*	0.962	0.825-1.123	
	BA vs. AA	Wang *et al.*	0.909	0.706-1.169	Fixed
		Sak *et al.*	0.788	0.596-1.042	
		Zhi *et al.*	0.911	0.704-1.180	
	BA+BB vs. AA	Wang *et al.*	0.926	0.728-1.177	Fixed
		Sak *et al.*	0.831	0.634-1.089	
		Zhi *et al.*	0.922	0.719-1.181	
	BB vs. AA	Wang *et al.*	1.015	0.726-1.421	Fixed
		Sak *et al.*	1.621	0.664-3.957	
		Zhi *et al.*	1.004	0.710-1.421	
	BB vs. AA+AB	Wang *et al.*	0.991	0.775-1.266	Fixed
		Sak *et al.*	1.715	0.704-4.174	
		Zhi *et al.*	0.982	0.765-1.261	
XRCC1-rs25487	B vs. A	Figueroa *et al.*	1.025	0.985-1.066	Fixed
		Matullo *et al.*	1.033	0.994-1.072	
		Stern *et al.*	1.030	0.992-1.069	
		Stern *et al.*	1.032	0.994-1.072	
		Mittal *et al.*	1.026	0.988-1.065	
		Arizono *et al.*	1.033	0.995-1.073	

Mittal *et al.*	1.027	0.989-1.067
Sak *et al.*	1.034	0.995-1.074
Sanyal *et al.*	1.027	0.989-1.067
Matullo *et al.*	1.036	0.997-1.076
Fontana *et al.*	1.032	0.994-1.071
Broberg *et al.*	1.029	0.992-1.069
Matullo *et al.*	1.030	0.992-1.069
Shen *et al.*	1.033	0.994-1.072
Ramaniuk *et al.*	1.033	0.995-1.073
Zhi *et al.*	1.025	0.987-1.064
Wang *et al.*	1.034	0.996-1.074
Andrew *et al.*	1.037	0.997-1.078
Kelsey *et al.*	1.032	0.994-1.072
Huang *et al.*	1.030	0.991-1.070
Gao *et al.*	1.027	0.989-1.067
Hamano *et al.*	1.031	0.993-1.070
Berhane *et al.*	1.026	0.988-1.065
Mittal *et al.*	1.028	0.990-1.068
Abe *et al.*	1.031	0.993-1.072
vanGils *et al.*	1.033	0.995-1.072
Xu *et al.*	1.024	0.987-1.064
Ritchey *et al.*	1.029	0.991- 1.068
Hirata *et al.*.	1.030	0.992-1.070
Dhillon *et al.*	1.032	0.994-1.072
Kuasne *et al.*	1.030	0.992-1.070
Zhu *et al.*	1.022	0.983-1.062
Chen *et al.*	1.031	0.993-1.070

	Chen *et al.*	1.026	0.988-1.066	
	Rybicki *et al.*	1.034	0.995-1.074	
	Rybicki *et al.*	1.033	0.994-1.073	
	Agalliu *et al.*	1.044	1.003-1.086	
	Agalliu *et al.*	1.032	0.994-1.071	
	Hirata *et al.*.	1.029	0.991-1.068	
BA vs. AA	Figueroa *et al.*	1.027	0.971-1.086	Fixed
	Matullo *et al.*	1.034	0.980-1.091	
	Stern *et al.*	1.031	0.977-1.088	
	Stern *et al.*	1.032	0.977-1.089	
	Mittal *et al.*	1.025	0.971-1.083	
	Arizono *et al.*	1.030	0.975-1.087	
	Mittal *et al.*	1.025	0.971-1.082	
	Sak *et al.*	1.034	0.979-1.092	
	Sanyal *et al.*	1.027	0.972-1.084	
	Matullo *et al.*	1.038	0.983-1.096	
	Fontana *et al.*	1.032	0.977-1.089	
	Broberg *et al.*	1.029	0.975-1.086	
	Matullo *et al.*	1.033	0.978-1.091	
	Shen *et al.*	1.035	0.980-1.093	
	Ramaniuk *et al.*	1.033	0.978-1.091	
	Zhi *et al.*	1.026	0.971-1.083	
	Wang *et al.*	1.039	0.984-1.097	
	Andrew *et al.*	1.026	0.969-1.085	
	Kelsey *et al.*	1.021	0.966-1.078	
	Huang *et al.*	1.031	0.976-1.090	
	Gao *et al.*	1.031	0.977-1.089	

	Hamano *et al.*	1.033	0.979-1.091	
	Berhane *et al.*	1.031	0.976-1.088	
	Mittal *et al.*	1.037	0.982-1.095	
	Abe *et al.*	1.035	0.980-1.093	
	vanGils *et al.*	1.034	0.980-1.092	
	Xu *et al.*	1.023	0.969-1.080	
	Ritchey *et al.*	1.036	0.981-1.093	
	Hirata *et al.*.	1.034	0.979-1.092	
	Dhillon *et al.*	1.034	0.980-1.092	
	Kuasne *et al.*	1.038	0.984-1.096	
	Zhu *et al.*	1.028	0.973-1.086	
	Chen *et al.*	1.032	0.978-1.090	
	Chen *et al.*	1.027	0.972-1.084	
	Rybicki *et al.*	1.037	0.981-1.095	
	Rybicki *et al.*	1.035	0.979-1.093	
	Agalliu *et al.*	1.048	0.990-1.110	
	Agalliu *et al.*	1.035	0.981-1.093	
	Hirata *et al.*.	1.036	0.981-1.093	
BA+BB vs. AA	Figueroa *et al.*	1.033	0.979-1.089	Fixed
	Matullo *et al.*	1.042	0.990-1.096	
	Stern *et al.*	1.038	0.986-1.092	
	Stern *et al.*	1.040	0.988-1.095	
	Mittal *et al.*	1.032	0.981-1.087	
	Arizono *et al.*	1.040	0.988-1.095	
	Mittal *et al.*	1.033	0.981-1.087	
	Sak *et al.*	1.042	0.989-1.098	
	Sanyal *et al.*	1.034	0.982-1.089	
	Matullo *et al.*	1.046	0.994-1.102	

Fontana *et al.*	1.040	0.988-1.094
Broberg *et al.*	1.037	0.985-1.091
Matullo *et al.*	1.039	0.987-1.094
Shen *et al.*	1.042	0.990-1.097
Ramaniuk *et al.*	1.042	0.989-1.097
Zhi *et al.*	1.032	0.980-1.087
Wang *et al.*	1.046	0.994-1.101
Andrew *et al.*	1.039	0.985-1.096
Kelsey *et al.*	1.033	0.981-1.088
Huang *et al.*	1.038	0.985-1.094
Gao *et al.*	1.037	0.985-1.091
Hamano *et al.*	1.040	0.989-1.095
Berhane *et al.*	1.035	0.984-1.090
Mittal. *et al.*	1.041	0.989-1.096
Abe *et al.*	1.042	0.989-1.097
vanGils *et al.*	1.042	0.990-1.097
Xu *et al.*	1.030	0.978-1.084
Ritchey *et al.*	1.040	0.988-1.095
Hirata *et al.*.	1.040	0.988-1.095
Dhillon *et al.*	1.042	0.990-1.096
Kuasne *et al.*	1.043	0.990-1.097
Zhu *et al.*	1.031	0.979-1.087
Chen *et al.*	1.040	0.988-1.094
Chen *et al.*	1.033	0.981-1.088
Rybicki *et al.*	1.044	0.991-1.100
Rybicki *et al.*	1.042	0.990-1.098
Agalliu *et al.*	1.057	1.002-1.116

	Agalliu *et al.*	1.042	0.990-1.097	
	Hirata *et al.*.	1.040	0.988-1.095	
BB vs. AA	Figueroa *et al.*	1.040	0.954-1.132	Fixed
	Matullo *et al.*	1.057	0.973-1.147	
	Stern *et al.*	1.052	0.970-1.142	
	Stern *et al.*	1.059	0.975-1.150	
	Mittal *et al.*	1.043	0.960-1.133	
	Arizono *et al.*	1.062	0.978-1.153	
	Mittal *et al.*	1.046	0.963-1.136	
	Sak *et al.*	1.060	0.974-1.152	
	Sanyal *et al.*	1.048	0.965-1.139	
	Matullo *et al.*	1.063	0.978-1.155	
	Fontana *et al.*	1.056	0.973-1.146	
	Broberg *et al.*	1.053	0.970-1.143	
	Matullo *et al.*	1.050	0.966-1.140	
	Shen *et al.*	1.056	0.972-1.146	
	Ramaniuk *et al.*	1.060	0.975-1.152	
	Zhi *et al.*	1.042	0.959-1.131	
	Wang *et al.*	1.057	0.973-1.148	
	Andrew *et al.*	1.076	0.987-1.173	
	Kelsey *et al.*	1.067	0.981-1.160	
	Huang *et al.*	1.050	0.966-1.142	
	Gao *et al.*	1.044	0.961-1.134	
	Hamano *et al.*	1.054	0.971-1.145	
	Berhane *et al.*	1.040	0.957-1.129	
	Mittal *et al.*	1.044	0.960-1.134	
	Abe *et al.*	1.052	0.968-1.144	

	vanGils *et al.*	1.057	0.973-1.147	
	Xu *et al.*	1.046	0.963-1.136	
	Ritchey *et al.*	1.044	0.961-1.133	
	Hirata *et al.*.	1.049	0.966-1.139	
	Dhillon *et al.*	1.056	0.973-1.147	
	Kuasne *et al.*	1.049	0.965-1.139	
	Zhu *et al.*	1.031	0.948-1.121	
	Chen *et al.*	1.053	0.970-1.143	
	Chen *et al.*	1.045	0.962-1.135	
	Rybicki *et al.*	1.058	0.973-1.150	
	Rybicki *et al.*	1.057	0.972-1.149	
	Agalliu *et al.*	1.077	0.988-1.175	
	Agalliu *et al.*	1.052	0.970-1.142	
	Hirata *et al.*.	1.043	0.961-1.133	
BB vs. AA+AB	Figueroa *et al.*	1.030	0.951-1.115	Fixed
	Matullo *et al.*	1.043	0.966-1.125	
	Stern *et al.*	1.039	0.963-1.121	
	Stern *et al.*	1.045	0.968-1.129	
	Mittal *et al.*	1.035	0.958-1.118	
	Arizono *et al.*	1.048	0.971-1.132	
	Mittal *et al.*	1.040	0.963-1.123	
	Sak *et al.*	1.046	0.967-1.130	
	Sanyal *et al.*	1.038	0.961-1.121	
	Matullo *et al.*	1.046	0.968-1.130	
	Fontana *et al.*	1.043	0.967-1.126	
	Broberg *et al.*	1.041	0.964-1.123	
	Matullo *et al.*	1.036	0.960-1.119	

		Shen *et al.*	1.041	0.964-1.124	
		Ramaniuk *et al.*	1.046	0.968-1.130	
		Zhi *et al.*	1.031	0.955-1.114	
		Wang *et al.*	1.041	0.964-1.124	
		Andrew *et al.*	1.067	0.984-1.156	
		Kelsey *et al.*	1.061	0.982-1.146	
		Huang *et al.*	1.038	0.960-1.122	
		Gao *et al.*	1.031	0.955-1.114	
		Hamano *et al.*	1.038	0.961-1.121	
		Berhane *et al.*	1.027	0.951-1.109	
		Mittal. *et al.*	1.026	0.950-1.109	
		Abe *et al.*	1.038	0.960-1.122	
		vanGils *et al.*	1.042	0.965-1.125	
		Xu *et al.*	1.035	0.959-1.117	
		Ritchey *et al.*	1.031	0.955-1.113	
		Hirata *et al.*.	1.036	0.959-1.118	
		Dhillon *et al.*	1.041	0.964-1.124	
		Kuasne *et al.*	1.030	0.954-1.112	
		Zhu *et al.*	1.021	0.944-1.103	
		Chen *et al.*	1.039	0.963-1.122	
		Chen *et al.*	1.035	0.958-1.117	
		Rybicki *et al.*	1.042	0.964-1.126	
		Rybicki *et al.*	1.043	0.965-1.127	
		Agalliu *et al.*	1.055	0.973-1.143	
		Agalliu *et al.*	1.039	0.963-1.121	
		Hirata *et al.*.	1.030	0.954-1.112	
XRCC1-rs1799782	B vs. A	Huang *et al.*	1.048	0.927-1.185	Random

	Andrew *et al.*	1.056	0.935-1.194	
	Figueroa *et al.*	1.040	0.917-1.178	
	Matullo *et al.*	1.045	0.927-1.178	
	Stern *et al.*	1.047	0.935-1.174	
	Stern *et al.*	1.062	0.948- 1.189	
	Mittal *et al.*	1.033	0.917-1.163	
	Mittal *et al.*	1.038	0.920-1.172	
	Fontana *et al.*	1.040	0.925-1.170	
	Wang *et al.*	1.016	0.908-1.136	
	Sak *et al.*	1.047	0.927-1.183	
	Matullo *et al.*	1.059	0.943-1.191	
	Agalliu *et al.*	1.045	0.928-1.176	
	Hamano *et al.*	1.022	0.912-1.144	
	Hirata *et al.*.	1.029	0.912-1.160	
	Zhu *et al.*	1.020	0.907-1.148	
	vanGils *et al.*	1.050	0.934-1.180	
	Xu *et al.*	1.071	0.956-1.199	
	Agalliu *et al.*	1.059	0.938-1.196	
	Mittal *et al.*	1.035	0.918-1.168	
BA vs. AA	Huang *et al.*	0.989	0.869-1.126	Random
	Andrew *et al.*	0.994	0.872-1.134	
	Figueroa *et al.*	0.985	0.863-1.124	
	Matullo *et al.*	0.987	0.870-1.119	
	Stern *et al.*	0.984	0.880-1.116	
	Stern *et al.*	1.004	0.892-1.131	
	Mittal *et al.*	0.978	0.864-1.107	
	Mittal *et al.*	0.983	0.866-1.115	

	Fontana *et al.*	0.987	0.875-1.114	
	Wang *et al.*	0.969	0.857-1.095	
	Sak *et al.*	0.989	0.870-1.125	
	Matullo *et al.*	1.002	0.886-1.134	
	Agalliu *et al.*	0.989	0.873-1.119	
	Hamano *et al.*	0.961	0.869-1.062	
	Hirata *et al.*.	0.969	0.859-1.092	
	Zhu *et al.*	0.974	0.855-1.109	
	vanGils *et al.*	0.993	0.878-1.124	
	Xu *et al.*	1.013	0.903-1.137	
	Agalliu *et al.*	0.999	0.876-1.139	
	Mittal *et al.*	0.993	0.875-1.126	
BA+BB vs. AA	Huang *et al.*	1.021	0.890-1.171	Random
	Andrew *et al.*	1.027	0.894-1.180	
	Figueroa *et al.*	1.014	0.882-1.167	
	Matullo *et al.*	1.018	0.891-1.164	
	Stern *et al.*	1.022	0.900-1.160	
	Stern *et al.*	1.037	0.914-1.177	
	Mittal *et al.*	1.006	0.882-1.148	
	Mittal *et al.*	1.012	0.885-1.158	
	Fontana *et al.*	1.017	0.895-1.156	
	Wang *et al.*	0.992	0.873-1.127	
	Sak *et al.*	1.020	0.890-1.169	
	Matullo *et al.*	1.034	0.907-1.179	
	Agalliu *et al.*	1.019	0.893-1.162	
	Hamano *et al.*	0.989	0.880-1.111	
	Hirata *et al.*.	0.998	0.876-1.136	

	Zhu *et al.*	0.997	0.872-1.141	
	vanGils *et al.*	1.024	0.899-1.167	
	Xu *et al.*	1.047	0.926-1.185	
	Agalliu *et al.*	1.031	0.898-1.183	
	Mittal *et al.*	1.015	0.887-1.162	
BB vs. AA	Huang *et al.*	1.537	1.195-1.976	Fixed
	Andrew *et al.*	1.603	1.237-2.076	
	Figueroa *et al.*	1.493	1.160-1.920	
	Matullo *et al.*	1.524	1.187-1.958	
	Stern *et al.*	1.525	1.188-1.958	
	Stern *et al.*	1.525	1.188-1.958	
	Mittal *et al.*	1.514	1.178-1.946	
	Mittal *et al.*	1.520	1.182-1.956	
	Fontana *et al.*	1.525	1.188-1.958	
	Wang *et al.*	1.392	1.069-1.813	
	Sak *et al.*	1.540	1.196-1.982	
	Matullo *et al.*	1.525	1.188-1.958	
	Agalliu *et al.*	1.525	1.188-1.958	
	Hamano *et al.*	1.533	1.185-1.985	
	Hirata *et al.*.	1.541	1.180-2.013	
	Zhu *et al.*	1.359	1.180-2.013	
	vanGils *et al.*	1.525	1.188-1.958	
	Xu *et al.*	1.762	1.341-2.316	
	Agalliu *et al.*	1.571	1.216-2.028	
	Mittal *et al.*	1.477	1.144--1.908	
BB vs. AA+AB	Huang *et al.*	1.483	1.164-1.890	Fixed
	Andrew *et al.*	1.539	1.200-1.973	

		Figueroa *et al.*	1.444	1.133-1.842	
		Matullo *et al.*	1.473	1.157-1.875	
		Stern *et al.*	1.474	1.159-1.875	
		Stern *et al.*	1.474	1.159-1.875	
		Mittal *et al.*	1.465	1.150-1.865	
		Mittal *et al.*	1.469	1.153-1.873	
		Fontana *et al.*	1.474	1.155-1.882	
		Wang *et al.*	1.362	1.057-1.755	
		Sak *et al.*	1.486	1.165-1.895	
		Matullo *et al.*	1.474	1.159-1.875	
		Agalliu *et al.*	1.474	1.159-1.875	
		Hamano *et al.*	1.508	1.176-1.933	
		Hirata *et al.*.	1.521	1.176-1.968	
		Zhu *et al.*	1.326	1.000-1.757	
		vanGils *et al.*	1.474	1.159-1.875	
		Xu *et al.*	1.627	1.251-2.117	
		Agalliu *et al.*	1.512	1.182-1.933	
		Mittal *et al.*	1.427	1.116-1.825	
XRCC2-rs3218536	B vs. A	Nowacka-Zawisza *et al.*	0.930	0.772-1.120	Fixed
		Matullo *et al.*	0.939	0.778-1.133	
		Figueroa *et al.*	1.064	0.649-1.744	
	BA vs. AA	Nowacka-Zawisza *et al.*	0.997	0.813-1.224	Fixed
		Matullo *et al.*	0.996	0.811-1.223	
		Figueroa *et al.*	1.196	0.701-2.041	
	BA+BB vs. AA	Nowacka-Zawisza *et al.*	0.961	0.787-1.175	Fixed
		Matullo *et al.*	0.966	0.789-1.182	
		Figueroa *et al.*	1.132	0.672-10.909	

	BB vs. AA	Nowacka-Zawisza *et al.*	0.438	0.177-1.080	Fixed
		Matullo *et al.*	0.453	0.171-1.198	
		Figueroa *et al.*	0.353	0.031-3.954	
	BB vs. AA+AB	Nowacka-Zawisza *et al.*	0.438	0.177-1.079	Fixed
		Matullo *et al.*	0.455	0.172-1.201	
		Figueroa *et al.*	0.345	0.030-3.854	
XRCC3-rs861539	B vs. A	Narter *et al.*	1.043	0.945-1.151	Random
		Fontana *et al.*	1.018	0.910-1.140	
		Matullo *et al.*	0.990	0.885-1.106	
		Zhu *et al.*	0.997	0.889-1.118	
		Andrew *et al.*	1.000	0.882-1.133	
		Gangwar *et al.*	1.008	0.897-1.133	
		Figueroa *et al.*	0.998	0.881-1.130	
		Mittle *et al.*	1.009	0.898-1.133	
		Matullo *et al.*	0.996	0.886-1.120	
		Sanyal. *et al.*	1.000	0.889-1.125	
		Shen *et al.*	1.023	0.913-1.146	
		Narter *et al.*	1.043	0.945-1.151	
		Wu *et al.*	0.999	0.885-1.127	
		Broberg *et al.*	1.011	0.902-1.134	
		Stern *et al.*	0.997	0.888-1.120	
		Matullo *et al.*	1.012	0.901-1.137	
		Hao *et al.*	0.993	0.888-1.111	
		Nowacka-Zawisza *et al.*	1.023	0.914-1.146	
		Ritchey *et al.*	1.007	0.898-1.130	
		Dhillon *et al.*	1.013	0.903-1.137	
		Mandal. *et al.*	0.995	0.887-1.117	

	Hamano *et al.*	1.013	0.904-1.135	
	Dhillon *et al.*	1.013	0.903-1.137	
BA vs. AA	Narter *et al.*	1.034	0.909-1.176	Random
	Fontana *et al.*	1.036	0.911-1.178	
	Matullo *et al.*	1.005	0.897-1.126	
	Zhu *et al.*	1.034	0.906-1.181	
	Andrew *et al.*	1.039	0.904-1.194	
	Gangwar *et al.*	1.032	0.903-1.180	
	Figueroa *et al.*	1.022	0.889-1.175	
	Mittle *et al.*	1.033	0.904-1.181	
	Matullo *et al.*	1.019	0.892-1.165	
	Sanyal. *et al.*	1.035	0.905-1.183	
	Shen *et al.*	1.061	0.938-1.199	
	Narter *et al.*	1.034	0.909-1.176	
	Wu *et al.*	1.018	0.889-1.166	
	Broberg *et al.*	1.026	0.900-1.170	
	Stern *et al.*	1.020	0.893-1.164	
	Matullo *et al.*	1.036	0.907-1.184	
	Hao *et al.*	1.012	0.892-1.148	
	Nowacka-Zawisza *et al.*	1.032	0.904-1.178	
	Ritchey *et al.*	1.037	0.910-1.182	
	Dhillon *et al.*	1.056	0.934-1.195	
	Mandal. *et al.*	1.018	0.892-1.161	
	Hamano *et al.*	1.041	0.914-1.185	
	Dhillon *et al.*	1.056	0.934-1.195	
BA+BB vs. AA	Narter *et al.*	1.044	0.918-1.187	Random
	Fontana *et al.*	1.026	0.894-1.177	

	Matullo *et al.*	0.993	0.873-1.129	
	Zhu *et al.*	1.012	0.878-1.166	
	Andrew *et al.*	1.016	0.873-1.182	
	Gangwar *et al.*	1.019	0.883-1.175	
	Figueroa *et al.*	1.006	0.866-1.169	
	Mittle *et al.*	1.019	0.883-1.176	
	Matullo *et al.*	1.004	0.871-1.158	
	Sanyal. *et al.*	1.015	0.879-1.172	
	Shen *et al.*	1.047	0.915-1.198	
	Narter *et al.*	1.044	0.918-1.187	
	Wu *et al.*	1.005	0.868-1.163	
	Broberg *et al.*	1.016	0.883-1.170	
	Stern *et al.*	1.005	0.872-1.158	
	Matullo *et al.*	1.023	0.888-1.180	
	Hao *et al.*	0.999	0.871-1.146	
	Nowacka-Zawisza *et al.*	1.028	0.893-1.183	
	Ritchey *et al.*	1.021	0.887-1.175	
	Dhillon *et al.*	1.039	0.905-1.191	
	Mandal. *et al.*	1.003	0.871-1.155	
	Hamano *et al.*	1.027	0.894-1.181	
	Dhillon *et al.*	1.039	0.905-1.191	
BB vs. AA	Narter *et al.*	1.141	0.954-1.365	Random
	Fontana *et al.*	1.103	0.901-1.350	
	Matullo *et al.*	1.051	0.857-1.290	
	Zhu *et al.*	1.053	0.863-1.286	
	Andrew *et al.*	1.067	0.848-1.342	
	Gangwar *et al.*	1.086	0.881-1.339	

	Figueroa *et al.*	1.068	0.850-1.342	
	Mittle *et al.*	1.087	0.882-1.340	
	Matullo *et al.*	1.058	0.853-1.311	
	Sanyal. *et al.*	1.062	0.858-1.316	
	Shen *et al.*	1.107	0.899-1.364	
	Narter *et al.*	1.141	0.954-1.365	
	Wu *et al.*	1.071	0.857-1.337	
	Broberg *et al.*	1.099	0.895-1.350	
	Stern *et al.*	1.063	0.860-1.314	
	Matullo *et al.*	1.098	0.889-1.357	
	Hao *et al.*	1.077	0.877-1.322	
	Nowacka-Zawisza *et al.*	1.124	0.920-1.375	
	Ritchey *et al.*	1.073	0.874-1.317	
	Dhillon *et al.*	1.066	0.867-1.312	
	Mandal. *et al.*	1.063	0.864-1.308	
	Hamano *et al.*	1.081	0.879-1.328	
	Dhillon *et al.*	1.066	0.867-1.312	
BB vs. AA+AB	Narter *et al.*	1.103	0.936-1.300	Random
	Fontana *et al.*	1.071	0.886-1.295	
	Matullo *et al.*	1.044	0.859-1.268	
	Zhu *et al.*	1.024	0.853-1.230	
	Andrew *et al.*	1.032	0.837-1.272	
	Gangwar *et al.*	1.053	0.868-1.278	
	Figueroa *et al.*	1.043	0.844-1.288	
	Mittle *et al.*	1.054	0.869-1.278	
	Matullo *et al.*	1.034	0.847-1.264	
	Sanyal. *et al.*	1.029	0.846-1.252	

		Shen *et al.*	1.054	0.866-1.283	
		Narter *et al.*	1.103	0.936-1.300	
		Wu *et al.*	1.047	0.853-1.286	
		Broberg *et al.*	1.069	0.885-1.291	
		Stern *et al.*	1.038	0.853-1.264	
		Matullo *et al.*	1.062	0.873-1.292	
		Hao *et al.*	1.047	0.866-1.265	
		Nowacka-Zawisza *et al.*	1.087	0.903-1.309	
		Ritchey *et al.*	1.042	0.863-1.259	
		Dhillon *et al.*	1.029	0.853-1.241	
		Mandal. *et al.*	1.036	0.855-1.255	
		Hamano *et al.*	1.049	0.867-1.268	
		Dhillon *et al.*	1.029	0.853-1.241	
XRCC3-rs1799796	B vs. A	Matullo *et al.*	0.979	0.862-1.113	Fixed
		Mittle *et al.*	0.941	0.833-1.063	
		Wu *et al.*	1.059	0.908-1.234	
		Broberg *et al.*	0.997	0.886-1.121	
		Matullo *et al.*	0.939	0.830-1.064	
	BA vs. AA	Matullo *et al.*	1.007	0.845-1.200	Fixed
		Mittle *et al.*	0.917	0.775-1.086	
		Wu *et al.*	1.039	0.849-1.272	
		Broberg *et al.*	0.986	0.841-1.157	
		Matullo *et al.*	0.985	0.832-1.165	
	BA+BB vs. AA	Matullo *et al.*	0.995	0.842-1.175	Fixed
		Mittle *et al.*	0.920	0.784-1.079	
		Wu *et al.*	1.059	0.873-1.285	
		Broberg *et al.*	0.991	0.852-1.154	

		Matullo *et al.*	0.958	0.816-1.125	
	BB vs. AA	Matullo *et al.*	0.934	0.515-1.692	Random
		Mittle *et al.*	0.949	0.564-1.595	
		Wu *et al.*	1.077	0.608-1.910	
		Broberg *et al.*	1.075	0.715-1.614	
		Matullo *et al.*	0.811	0.598-1.100	
	BB vs. AA+AB	Matullo *et al.*	0.940	0.528-1.673	Random
		Mittle *et al.*	0.983	0.591-1.633	
		Wu *et al.*	1.070	0.602-1.904	
		Broberg *et al.*	1.096	0.739-1.625	
		Matullo *et al.*	0.836	0.625-1.120	
XRCC4-rs6869366	B vs. A	Chang *et al.*	0.853	0.701-1.038	Fixed
		Mandal. *et al.*	1.085	0.857-1.374	
		Mittal. *et al.*	1.038	0.812-1.327	
		Chang *et al.*	0.794	0.645-0.979	
	BA vs. AA	Chang *et al.*	0.936	0.736-1.190	Fixed
		Mandal. *et al.*	1.260	0.951-1.670	
		Mittal. *et al.*	1.196	0.897-1.595	
		Chang *et al.*	0.856	0.661-1.109	
	BA+BB vs. AA	Chang *et al.*	0.884	0.699-1.118	Fixed
		Mandal. *et al.*	1.200	0.911-1.582	
		Mittal. *et al.*	1.137	0.857-1.508	
		Chang *et al.*	0.806	0.626-1.037	
	BB vs. AA	Chang *et al.*	0.413	0.210-0.809	Fixed
		Mandal. *et al.*	0.474	0.197-1.141	
		Mittal. *et al.*	0.341	0.119-0.980	
		Chang *et al.*	0.413	0.210-0.809	

	BB vs. AA+AB	Chang *et al.*	0.469	0.242-0.910	Fixed
		Mandal. *et al.*	0.526	0.222-1.245	
		Mittal. *et al.*	0.401	0.141-1.134	
		Chang *et al.*	0.469	0.242-0.910	
XRCC4-rs28360071	B vs. A	Mandal. *et al.*	1.188	0.909-1.553	Fixed
		Mittal. *et al.*	1.382	1.064-1.795	
		Chang *et al.*	1.544	1.195-1.997	
	BA vs. AA	Mandal. *et al.*	1.129	0.818-1.558	Fixed
		Mittal. *et al.*	1.234	0.892-1.708	
		Chang *et al.*	1.261	0.913-1.741	
	BA+BB vs. AA	Mandal. *et al.*	1.179	0.865-1.608	Fixed
		Mittal. *et al.*	1.353	0.994-1.841	
		Chang *et al.*	1.447	1.073-1.952	
	BB vs. AA	Mandal. *et al.*	1.690	0.712-4.010	Fixed
		Mittal. *et al.*	2.417	1.141-5.116	
		Chang *et al.*	2.781	1.445-5.351	
	BB vs. AA+AB	Mandal. *et al.*	1.635	0.692-3.863	Fixed
		Mittal. *et al.*	2.255	1.071-4.747	
		Chang *et al.*	2.618	1.367-5.014	
XRCC4-rs1805377	B vs. A	Mandal. *et al.*	0.815	0.707-0.940	Random
		Luedeke *et al.*	0.808	0.695-0.939	
		Broberg *et al.*	0.820	0.717-0.938	
		Mittal. *et al.*	0.826	0.716-0.954	
		Figueroa *et al.*	0.884	0.740-1.056	
	BA vs. AA	Mandal. *et al.*	1.033	0.757-1.411	Random
		Luedeke *et al.*	0.997	0.768-1.293	
		Broberg *et al.*	1.018	0.781-1.325	

		Mittal. *et al.*	1.023	0.737-1.420	
		Figueroa *et al.*	0.983	0.754-1.282	
	BA+BB vs. AA	Mandal. *et al.*	0.934	0.689-1.266	Random
		Luedeke *et al.*	0.923	0.717-1.188	
		Broberg *et al.*	0.926	0.717-1.197	
		Mittal. *et al.*	0.952	0.694-1.306	
		Figueroa *et al.*	0.926	0.716-1.198	
	BB vs. AA	Mandal. *et al.*	0.750	0.432-1.304	Fixed
		Luedeke *et al.*	0.660	0.375-1.160	
		Broberg *et al.*	0.709	0.432-1.165	
		Mittal. *et al.*	0.902	0.536-1.516	
		Figueroa *et al.*	0.645	0.345-1.204	
	BB vs. AA+AB	Mandal. *et al.*	0.755	0.635-0.898	Fixed
		Luedeke *et al.*	0.705	0.572-0.867	
		Broberg *et al.*	0.750	0.632-0.890	
		Mittal. *et al.*	0.770	0.648-0.915	
		Figueroa *et al.*	0.804	0.606-1.066	
XRCC7-rs7003908	B vs. A	Hirata *et al.*.	1.122	0.670-1.876	Random
		Mandal. *et al.*	1.066	0.638-1.781	
		Wang *et al.*	1.257	0.791-1.997	
		Gangwar *et al.*	0.973	0.682-1.388	
		Zhi *et al.*	1.273	0.831-1.950	
		Hirata *et al.*.	1.136	0.683-1.887	
	BA vs. AA	Hirata *et al.*.	0.935	0.654-1.335	Random
		Mandal. *et al.*	0.960	0.658-1.398	
		Wang *et al.*	1.074	0.735-1.569	
		Gangwar *et al.*	0.893	0.661-1.206	

	Zhi *et al.*	1.101	0.790-1.533	
	Hirata *et al.*.	1.033	0.703-1.517	
BA+BB vs. AA	Hirata *et al.*.	1.075	0.630-1.834	Random
	Mandal. *et al.*	1.048	0.624-1.762	
	Wang *et al.*	1.241	0.742-2.078	
	Gangwar *et al.*	0.934	0.643-1.359	
	Zhi *et al.*	1.267	0.794-2.021	
	Hirata *et al.*.	1.146	0.668-1.966	
BB vs. AA	Hirata *et al.*.	1.190	0.443-3.191	Random
	Mandal. *et al.*	1.028	0.346-3.050	
	Wang *et al.*	1.546	0.680-3.517	
	Gangwar *et al.*	0.900	0.402-2.014	
	Zhi *et al.*	1.540	0.707-3.355	
	Hirata *et al.*.	1.102	0.402-3.019	
BB vs. AA+AB	Hirata *et al.*.	1.206	0.560-2.600	Random
	Mandal. *et al.*	1.021	0.413-2.526	
	Wang *et al.*	1.461	0.771-2.768	
	Gangwar *et al.*	0.939	0.466-1.892	
	Zhi *et al.*	1.473	0.794-2.729	
	Hirata *et al.*.	1.067	0.480-2.367	

B: mutated allele; A: wild allele

Supplementary table 3. *P* values of the Egger's test for the polymorphisms in *XRCC* genes.

Polymorphism	Subgroup	Egger'test *P* > |t|
XRCC1-rs915927	Overall	0.397
	Caucasian	0.297
	H-B	0.513
	BC	0.611
	PCa	/
XRCC1-rs25489	Overall	0.292
	Asian	0.607
	Caucasian	0.518
	H-B	0.211
	P-B	0.647
	N	0.121
	Y	0.830
	BC	0.297
	PCa	0853
XRCC1-rs3213245	Overall	0.075
	Asian	/
	Y	0.069
	BC	0.069
XRCC1-rs25487	Overall	0.235
	Asian	0.864
	Caucasian	0.988
	African	/
	Mixed	0.999
	H-B	0.211
	P-B	0.667
	N	0.350
	Y	0.247
	BC	0.652
	PCa	0.196
XRCC1-rs1799782	Overall	0.412
	H-B	0.717
	P-B	0.716
	N	/
	Y	0.948
	BC	0.693
	PCa	0.902
XRCC2-rs3218536	Overall	0.315
	Caucasian	0.331
	H-B	0.315
	Y	0.331
	BC	/
XRCC3-rs1799796	Overall	0.681
	H-B	0.248
	P-B	/
	Y	0.612
	BC	0.612

XRCC3-rs861539	Overall	0.065
	Asian	0.624
	Caucasian	0.059
	Mixed	0.308
	H-B	0.294
	P-B	0.274
	N	0.302
	Y	0.967
	BC	0.588
	PCa	0.536
XRCC4-rs28360071	Overall	**0.043**
	Asian	0.090
	H-B	0.090
	Y	0.090
	BC	/
XRCC4-rs1805377	Overall	0.094
	Asian	/
	Caucasian	0.370
	H-B	0.082
	Y	0.082
	BC	**0.009**
	PCa	/
XRCC4-rs6869366	Overall	0.107
	Asian	0.174
	H-B	0.174
	Y	0.174
	BC	/
	PCa	/
XRCC7-rs7003908	Overall	0.820
	Asian	0.648
	H-B	0.648
	Y	0.648
	BC	0.809
	PCa	/

PCa: prostate cancer; BC: bladder cancer; H-B: hospital-based; P-B: population-based; Y: study conformed to HWE; N: study did not conform to HWE.

Supplementary table 4. The PRISMA 2009 checklist for current meta-analysis and systematic review.

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	2-3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	4-5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4-5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5

Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6-7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	6-7
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	7
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	6-7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	7-8
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10-11
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each	9-10

		intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	9-10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10-11
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	11-12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13-14
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	15-16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	12-14
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	16

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: **www.prisma-statement.org**.